In diabetic, obese or MCD-induced NAFLD non-human primates, FGF21 (44) or FGF21 analogs (237) robustly reduce serum triglycerides, LDL-cholesterol, and VLDL-cholesterol while increasing HDL-cholesterol. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.